UroGen Pharma Ltd.
URGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$126,874 | -$102,244 | -$109,783 | -$110,820 |
| Dep. & Amort. | $1,186 | $1,705 | $1,817 | $1,773 |
| Deferred Tax | $0 | $0 | $0 | $15,324 |
| Stock-Based Comp. | $13,108 | $9,343 | $10,580 | $23,113 |
| Change in WC | $4,933 | $3,336 | -$6,306 | -$13,106 |
| Other Non-Cash | $10,881 | $11,484 | $16,133 | -$1,176 |
| Operating Cash Flow | -$96,766 | -$76,376 | -$87,559 | -$84,892 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$295 | -$194 | -$254 | -$752 |
| Net Acquisitions | $0 | $0 | -$1,314 | -$4,821 |
| Inv. Purchases | -$128,023 | -$49,832 | -$63,009 | -$51,898 |
| Inv. Sales/Matur. | $107,705 | $49,073 | $64,323 | $56,719 |
| Other Inv. Act. | $0 | $0 | $1,314 | $4,821 |
| Investing Cash Flow | -$20,613 | -$953 | $1,060 | $4,069 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $24,488 | $0 | $95,783 | $0 |
| Stock Issued | $151,169 | $67,358 | $1,351 | -$83 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $18,962 | $49,573 | $0 | $72,402 |
| Financing Cash Flow | $194,619 | $116,931 | $97,134 | $72,319 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $77,240 | $39,602 | $10,635 | -$8,504 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $95,823 | $56,221 | $45,586 | $54,090 |
| End Cash | $173,063 | $95,823 | $56,221 | $45,586 |
| Free Cash Flow | -$97,061 | -$76,570 | -$87,813 | -$85,644 |